Owing to their superior efficacy compared to chemotherapy, first- and second-generation EGFR TKIs, including erlotinib, gefitinib, and afatinib, are now approved for first-line treatment of patients with advanced NSCLC harboring sensitizing EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.